Agranulocyosis in beta thalassemia major patients treated with oral iron chelating agent (Deferiprone)

Oman Medical Journal

Volumn 23, Issue 4, 2008, Pages 275-277

  Wali, Yasser ^a   Al Shidhani, Azza ^a   Daar, Shahina ^a  

^a SULTAN QABOOS UNIVERSITY HOSPITAL   (Oman)

Author keywords

Deferiprone; Granulocytosis; Thalassemia

Indexed keywords

AMINOGLYCOSIDE; CEPHALOSPORIN; DEFERIPRONE; DEFEROXAMINE; GRANULOCYTE COLONY STIMULATING FACTOR; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM;

AGRANULOCYTOSIS; ARTICLE; BETA THALASSEMIA; CASE REPORT; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; PRESCHOOL CHILD; SEPSIS; SIDEROSIS;

EID: 84883297154     PISSN: 1999768X     EISSN: 20705204     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005 Sep;353(11):1135-1146.
2. Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 2005;56:157-171.
3. Barman Balfour JA, Foster RH. Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases. Drugs 1999 Sep;58(3):553-578.
4. Hoffbrand V. Deferiprone therapy for transfusional iron overload. Best Pract Res Clin Haematol 2005 Jun;18(Issue 2):299-317.
5. Piga A, Roggero S, Vinciguerra T, Sacchetti L, Gallo V, Longo F. Deferiprone: New insight. Ann N Y Acad Sci 2005;1054:169-174.
6. Huang YC, Chang JS, Wu KH, Peng CT. Regression of myocardial dysfunction after switching from desferrioxamine to deferiprone therapy in beta-thalassemia major patients. Hemoglobin 2006;30(2):229-238.
7. Porter JB. A risk-benefit assessment of iron-chelation therapy. Drug Saf 1997 Dec;17(6):407-421.
8. al-Refaie FN, Hershko C, Hoffbrand AV, Kosaryan M, Olivieri NF, Tondury P, et al. Results of long-term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators. Br J Haematol 1995 Sep;91(1):224-229.
9. Castriota-Scanderbeg A, Sacco M. Agranulocytosis, arthritis and systemic vasculitis in a patient receiving the oral iron chelator L1 (deferiprone). Br J Haematol 1997 Feb;96(2):254-255.
10. Kontoghiorghes GJ, Neocleous K, Kolnagou A. Benefits and risks of deferiprone in iron overload in Thalassaemia and other conditions: comparison of epidemiological and therapeutic aspects with deferoxamine. Drug Saf 2003;26(8):553-584.
11. Ayyub M, Ali W, Anwar M, Waqar A, Khan MN, Ijaz A, et al. Efficacy and adverse effects of oral iron chelator deferiprone (l1, 1,2-dimethyl-3-hydroxypyrid-4-one) in patients with beta thalassaemia major in Pakistan. J Ayub Med Coll Abbottabad 2005 Oct-Dec;17(4):12-15.
12. Cohen AR, Galanello R, Piga A, Dipalma A, Vullo C, Tricta F. Safety profile of the oral iron chelator deferiprone: a multicentre study. Br J Haematol 2000 Feb;108(2):305-312.
13. Naithani R, Chandra J, Sharma S. Safety of oral iron chelator deferiprone in young thalassaemics. Eur J Haematol 2005 Mar;74(3):217-220.
14. al-Refaie FN, Veys PA, Wilkes S, Wonke B, Hoffbrand AV. Agranulocytosis in a patient with thalassaemia major during treatment with the oral iron chelator, 1,2-dimethyl-3-hydroxypyrid-4-one. Acta Haematol 1993;89(2):86-90.
15. Henter JI, Karlén J. Fatal agranulocytosis after deferiprone therapy in a child with Diamond-Blackfan anemia. Blood 2007 Jun;109(12):5157-5159.
16. Cohen AR, Galanello R, Piga A, De Sanctis V, Tricta F. Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone. Blood 2003 Sep;102(5):1583-1587.
17. Hoffbrand AV, AL-Refaie F, Davis B, Siritanakatkul N, Jackson BF, Cochrane J, et al. Long-term trial of deferiprone in 51 transfusion-dependent iron overloaded patients. Blood 1998 Jan;91(1):295-300.
18. Shoenfeld Y, Weinberger A, Avishar R, Zamir R, Gazit E, Joshua H, et al. Familial leukopenia among Yemenite Jews. Isr J Med Sci 1978 Dec;14(12):1271-1274.
19. Shoenfeld Y, Alkan ML, Asaly A, Carmeli Y, Katz M. Benign familial leukopenia and neutropenia in different ethnic groups. Eur J Haematol 1988 Sep;41(3):273-277.
20. Daar S. Unpublished data, Personal communication. June 2008.
21. al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ. Efficacy and possible adverse effects of the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1) in thalassemia major. Blood 1992 Aug;80(3):593-599.